• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Inside Philanthropy

Inside Philanthropy

Who's Funding What & Why

Facebook LinkedIn X
  • Grant Finder
  • For Donors
  • Learn
    • State of American Philanthropy
    • Explainers
  • Articles
    • Arts and Culture
    • Civic
    • Economy
    • Education
    • Environment
    • Global
    • Health
    • Science
    • Social Justice
  • Places
  • Jobs
  • Search Our Site

With Donor Backing, Hard-Hit Bronx Becomes a Center for COVID-19 Research

Paul Karon | July 13, 2020

Share on Facebook Share on LinkedIn Share on X Share via Email
Banner for article With Donor Backing
new yorkers wait outside a Covid19 walk-in testing site in The Bronx in april. The borough has been among the hardest hit during the pandemic. Steve Sanchez Photos/shutterstock

Billionaire Michael F. Price, who runs the New York-based MFP Investors hedge fund, has long supported medical research and community health in low-income neighborhoods of New York City. For example, funding from his Price Family Foundation has gone for decades to the Bronx-based Montefiore Medical Center hospital and to the Montefiore-affiliated Albert Einstein College of Medicine.

But earlier this year, when COVID-19 struck with particular ferocity in New York City, the Bronx was one of the boroughs hit the hardest. That put the doctors at Montefiore right in the center of the crisis, tasked with treating a flood of patients suffering a barely understood disease. As of a few weeks ago, Montefiore had treated and discharged 5,000 COVID-19 patients.

The dire situation in the Bronx also created opportunities to gain expertise and knowledge. Few places in the United States could rival the clinicians at Montefiore for experience with COVID-19, enabling cross-pollination of ideas and knowledge between clinicians and the researchers at Einstein. Price and his foundation recognized this as an opportunity.

“The idea is that Montefiore and Einstein have a unique capability to translate clinical practice into research and research into practice,” said Joanne Duhl, executive director of the Price Family Foundation. So early last month, the foundation committed a matching grant of $1 million to support COVID-19 research at the Einstein College of Medicine.

The grant quickly had one desired effect—within weeks, it drew an additional $1 million in donations, some from first-time donors to the medical school. “One of our objectives was to bring in other people and shine a light on these institutions in the Bronx that are treating patients and doing important, cutting-edge research,” Duhl said.

The new funding enabled research leaders at Einstein to fund several coronavirus-related research projects, said Harris Goldstein, MD, associate dean for scientific resources and professor of pediatrics, and professor of microbiology and immunology at Einstein. “A couple of months ago, no one was focused on COVID,” said Goldstein. Shifting these scientists into coronavirus and COVID-19 projects rapidly would take funding. “That’s where Price was critical.”

The emergency nature of COVID-19 forced institutions and researchers to reorder their priorities—whatever they were working on had to be put on the back burner. COVID-19 was now the pressing issue. This has been true at centers around the country and the world: Researchers with any sort of background relevant to the coronavirus or COVID-19 are now looking for ways to understand and contain the disease, identify treatments, and develop vaccines.

Among the newly launched research projects at Einstein is a double-blind study of convalescent plasma as a COVID-19 treatment. While there are some indications that plasma from COVID-19 survivors could be beneficial to sick patients, double-blind studies are needed to show the therapeutic value more concretely. Another study seeks to understand the overactive and deadly immune response known as a cytokine storm. Another is looking at how artificial intelligence techniques developed for facial recognition systems could be used to scan chest X-rays and more rapidly diagnose COVID-19.

Other studies involve basic research to explore the possibility of tweaking existing drugs to make them effective against COVID-19, said Goldstein, as well as techniques to guide the development of new drugs. Another seeks to understand why most children don’t get sick from coronavirus infection.

Additional studies have already been launched or are in the process of being approved.

When the COVID-19 emergency started earlier in the spring, a chorus of philanthropy, nonprofit and public health officials all warned that the same vulnerable and marginalized populations that had long experienced disproportionate health burdens would be in particular danger as the pandemic spread. This indeed came to pass in the Bronx, one of the poorest sections of New York City, and one with a large Hispanic population. In that neighborhood, explained Duhl, COVID-19 didn’t so much exacerbate a vulnerable situation as reveal it. “It affirmed what we were doing, more so than ever,” she said.

Featured

The WHO Foundation: Applying a “Start-up Mentality” to the Challenges of Global Health

Five Questions for Lim Seok Hui, CEO of the Philanthropy Asia Alliance

This New Global Funder Is All About Proximate, On-the-Ground Giving in Africa

Melinda French Gates Charts a Course for a “New Chapter.” Here Are Some Takeaways

A Global Relief Organization Keeps the Spigot Open for Community Healthcare Providers Closer to Home

How Kellogg and Partner Philanthropies Are Funding in Haiti, a Country Beset by Crisis

A Skoll Award Winner Finds a Proximate Solution for School-Based Nutrition in Africa

How the Segal Family Foundation Funds Globally, Acts Locally

A Public-Private Cancer Funder Backs Team Science and Targets Inequities in Care and Outcomes

On/Go: Healthcare Entrepreneur Ron Gutman on Championing Humanitarian Causes

Where is MacKenzie Scott’s Global Giving Headed? Here’s What the Latest Data Tells Us

With “A Little Courage,” Ipas Is Shifting Money to the Front Lines of Abortion and Contraceptive Access

Big Pledges Won’t Solve Our Climate and Health Crisis If Those Who Need the Money Can’t Access It

“The Solutions Are There.” Funding Challenge Backs Community-Led Efforts to Save Mothers and Infants

Three Ways the Gates Foundation is Supporting the U.N.’s Sustainable Development Goals

Gates Leans into mRNA Technology for Vaccine Capacity in Low and Middle-Income Countries

This Year at the UNGA, Philanthropies Unite Behind Democracy and Locally Led Development

This Bespoke Funding Intermediary Focuses Donors on a Dozen Highly Vetted Global Grantees

Global Lack of Access to Eye Care Exacts a Great Cost. But This Organization Is Stepping Up

Gates Remains Among the Few in Philanthropy to Drive Research for an HIV Vaccine

This Women’s Donor Collective Invites its Members to “Experience Philanthropy Differently”

A Global Philanthropic Competition to Save the Lives of Mothers and Babies

Type 1 Diabetes Is an Overlooked Global Threat. This Health Funder Has Made it a Top Priority

Can an Aging Population Stay Healthy? Two Global Funders Hope to Unlock the Secrets of Resilience

How the India Philanthropy Alliance Engages a Growing Donor Base

How Christy Turlington Burns Uses Awareness and Advocacy to Put Mothers First

Beyond Borders: A Regional Look at MacKenzie Scott’s Global Giving

Inside This Abortion Care Backer’s Move to an “Anti-Colonialist” Decision-Making Model

Research Is Critical for Effective Aid. So Why Aren’t Researchers from the Global South Getting Funded?

Bloomberg’s Commitment to Curb Tobacco Use Now Totals $1.5 Billion. Here’s the Latest Move

Filed Under: IP Articles Tagged With: Diseases, Front Page - More Article, Front Page Most Recent, FrontPageMore, Health, Hospitals, Science, Science Research

Primary Sidebar

Find A Grant Square Banner

Newsletter

Donor Advisory Center Banner
Consultants Directory Banner

Philanthropy Jobs

Check out our Philanthropy Jobs Center or click a job listing for more information.

Footer

  • LinkedIn
  • X
  • Facebook

Quick Links

About Us
Contact Us
Consultants Directory
FAQ & Help
Terms of Use
Privacy Policy

Become a Subscriber

Individual Subscriptions ▶︎
Multi-User Subscriptions ▶︎

© 2024 - Inside Philanthropy